RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pathology and Oncology Research

• Publication date

  2012-06-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12253-011-9485-5PMID 22729835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status.

  2011cited by this paper
• Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression

  2010cited by this paper
• Lung tissue regeneration after induced injury in Runx3 KO mice

  2010cited by this paper
• Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer

  2010influential reference
• EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

  2009cited by this paper
• RUNX3 Attenuates β-Catenin/T Cell Factors in Intestinal Tumorigenesis

  2009cited by this paper
• EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

  2009cited by this paper
• Runx3 expression in gastrointestinal tract epithelium: resolving the controversy

  2009cited by this paper
• RUNX3 Has an Oncogenic Role in Head and Neck Cancer

  2009cited by this paper
• RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes.

  2008cited by this paper
• Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung.

  2008cited by this paper
• A personalized approach to cancer treatment: how biomarkers can help.

  2008cited by this paper
• RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.

  2008cited by this paper
• TRARESA: a tissue microarray‐based hospital system for biomarker validation and discovery

  2008cited by this paper
• RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression

  2008cited by this paper
• Genetic Mapping in Human Disease

  2008cited by this paper
• Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines

  2007cited by this paper
• Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas.

  2007cited by this paper
• Detection of epidermal growth factor receptor variations by partially denaturing HPLC.

  2007cited by this paper
• Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

  2006cited by this paper
• Epigenetic inactivation of the RUNX3 gene in lung cancer.

  2006cited by this paper
• RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.

  2006cited by this paper
• Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.

  2006cited by this paper
• High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer

  2006cited by this paper
• RUNX3 protein is overexpressed in human basal cell carcinomas

  2006cited by this paper
• Spreading of methylation within RUNX3 CpG island in gastric cancer

  2006cited by this paper
• The molecular epidemiology of lung cancer.

  2006cited by this paper
• Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk.

  2006cited by this paper
• The RUNX3 Tumor Suppressor Upregulates Bim in GastricEpithelial Cells Undergoing Transforming Growth Factorβ-Induced Apoptosis

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Expression of RUNX3 protein in human lung adenocarcinoma: Implications for tumor progression and prognosis

  2005cited by this paper
• RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization.

  2005cited by this paper
• Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence

  2005cited by this paper
• Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas

  2005cited by this paper
• In search of the holy grail: lung cancer biomarkers.

  2004cited by this paper
• Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines

  2004cited by this paper
• Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer.

  2004cited by this paper
• p53 from pathway to therapy

  2004cited by this paper
• Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy.

  2004cited by this paper
• Early detection of lung cancer: role of biomarkers

  2003cited by this paper
• Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers.

  2003cited by this paper
• Promoter hypermethylation of tumor suppressor and tumor‐related genes in non‐small cell lung cancers

  2003cited by this paper
• Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.

  2003cited by this paper
• Causal relationship between the loss of RUNX3 expression and gastric cancer.

  2002cited by this paper
• Smoking molecular damage in bronchial epithelium

  2002cited by this paper
• The new World Health Organization classification of lung tumours

  2001cited by this paper
• Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer.

  2001cited by this paper
• The RUNX3 gene--sequence, structure and regulated expression.

  2001cited by this paper
• Molecular epidemiology of lung cancer.

  1999cited by this paper
• Interaction and Functional Cooperation of PEBP2/CBF with Smads

  1999cited by this paper
• Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis.

  1998cited by this paper
• Genetic polymorphism of CYP2D6 and lung cancer risk.

  1998cited by this paper
• Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens.

  1998cited by this paper
• The molecular epidemiology of lung cancer.

  1997cited by this paper
• Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies.

  1997cited by this paper
• Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies.

  1997cited by this paper
• Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas.

  1996cited by this paper
• The effect of tobacco on lung cancer risk depends on CYP2D6 activity.

  1996cited by this paper
• Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

  1996influential reference
• Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition.

  1992cited by this paper
• Effect of cohort differences in smoking prevalence on models of lung cancer susceptibility

  1992cited by this paper
• What are the odds that smoking will kill you?

  1987cited by this paper

• Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations

  2024cites this paper
• Identification of a prognostic signature in colorectal cancer using combinatorial algorithm‐driven analysis

  2022cites this paper
• Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications

  2021cites this paper
• HistoClean: Open-source software for histological image pre-processing and augmentation to improve development of robust convolutional neural networks

  2021cites this paper
• Interplay of microRNAs to genetic, epigenetic, copy number variations of cervical cancer related genes.

  2020cites this paper
• In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

  2020cites this paper
• Lung Cancer Staging and Associated Genetic and Epigenetic Events

  2020cites this paper
• Runt-related transcription factor 2 in pulmonary fibrosis

  2019cites this paper
• Runx3 and Cell Fate Decisions in Pancreas Cancer.

  2017cites this paper
• Clinical Epigenetics of Lung Cancer

  2017cites this paper
• An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis

  2016cites this paper
• Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis

  2015cites this paper
• Epigenetics of lung cancer.

  2015cites this paper
• Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells

  2015cites this paper
• Clinicopathological significance and potential drug target of rUnX3 in non-small cell lung cancer: a meta-analysis the mechanism of initiation, progression, and identification of prognostic markers

  2015cites this paper
• Clinicopathological significance and potential drug target of rUnX3 in non-small cell lung cancer: a meta-analysis the mechanism of initiation, progression, and identification of prognostic markers

  2015cites this paper
• Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis.

  2014influential citation
• The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer

  2013cites this paper
• Association between P16INK4a Promoter Methylation and Non-Small Cell Lung Cancer: A Meta-Analysis

  2013cites this paper
• Linear Decay of Retrotransposon Antisense Bias across Genes Is Contingent upon Tissue Specificity

  2013cites this paper